Protagonist Therapeutics Inc Stock News

Worldwide collaboration agreement executed with Takeda Pharmaceuticals, including a $300 million upfront payment for rusfertide in polycythemia vera and other hematological indications Cash runway ext

- Trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45% without phlebotomy - Rusfertide was associated with

NEWARK, CA / ACCESSWIRE / February 20, 2024 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on February 15, 2024, it issued inducement awards to Sid Reddy, the Company's recently hi

JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively. NEWARK, CA / ACC

Per the deal, Protagonist (PTGX) will grant exclusive rights to Takeda to market its late-stage rare hematology drug. In return, Takeda will make an upfront payment of $300 million.

Protagonist Therapeutics is developing two parallel programs in different disease areas and has recovered in market valuation. The company will present important data on hematocrit control and iron de

NEWARK, CA / ACCESSWIRE / November 1, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.

Protagonist Therapeutics, Inc.'s oral IL-23 drug for psoriasis, JNJ-2113, must show non-inferior efficacy to Johnson & Johnson's injectable Tremfya before further development. JNJ-2113 is the only ora

NEWARK, CA / ACCESSWIRE / September 5, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.

Protagonist Therapeutics focuses on peptide-based drugs, primarily rusfertide, which is undergoing a Phase 3 trial for polycythemia vera. Financially, PTGX is robust with $313.4M in assets and a cash

Protagonist Therapeutics (PTGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

The consensus price target hints at a 25.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND

Protagonist Therapeutics (PTGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

The average of price targets set by Wall Street analysts indicates a potential upside of 38% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questiona